메뉴 건너뛰기




Volumn 19, Issue 8, 2013, Pages 1227-1232

Impact of t(11;14)(q13;q32) on the outcome of autologous hematopoietic cell transplantation in multiple myeloma

Author keywords

Autologous transplantation; Cytogenetics; Myeloma; T(11; 14)

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; LENALIDOMIDE; MELPHALAN; THALIDOMIDE;

EID: 84880436838     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.05.017     Document Type: Article
Times cited : (34)

References (33)
  • 2
    • 80053111637 scopus 로고    scopus 로고
    • Approach to the treatment of multiple myeloma: a clash of philosophies
    • Rajkumar S.V., Gahrton G., Bergsagel P.L. Approach to the treatment of multiple myeloma: a clash of philosophies. Blood 2011, 118:3205-3211.
    • (2011) Blood , vol.118 , pp. 3205-3211
    • Rajkumar, S.V.1    Gahrton, G.2    Bergsagel, P.L.3
  • 3
    • 33847369790 scopus 로고    scopus 로고
    • Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): consensus statement
    • Dispenzieri A., Rajkumar S.V., Gertz M.A., et al. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007, 82:323-341.
    • (2007) Mayo Clin Proc , vol.82 , pp. 323-341
    • Dispenzieri, A.1    Rajkumar, S.V.2    Gertz, M.A.3
  • 4
    • 10744223381 scopus 로고    scopus 로고
    • Genetics and cytogenetics of multiple myeloma: a workshop report
    • Fonseca R., Barlogie B., Bataille R., et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004, 64:1546-1558.
    • (2004) Cancer Res , vol.64 , pp. 1546-1558
    • Fonseca, R.1    Barlogie, B.2    Bataille, R.3
  • 5
    • 79956039754 scopus 로고    scopus 로고
    • Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2
    • Munshi N.C., Anderson K.C., Berqsagel P.L., et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011, 117:4696-4700.
    • (2011) Blood , vol.117 , pp. 4696-4700
    • Munshi, N.C.1    Anderson, K.C.2    Berqsagel, P.L.3
  • 6
    • 72949085546 scopus 로고    scopus 로고
    • Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines
    • Kumar S.K., Mikhael J.R., Buadi F.K., et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. Mayo Clin Proc 2009, 84:1095-1110.
    • (2009) Mayo Clin Proc , vol.84 , pp. 1095-1110
    • Kumar, S.K.1    Mikhael, J.R.2    Buadi, F.K.3
  • 7
    • 33847197966 scopus 로고    scopus 로고
    • Apractical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy
    • Stewart A.K., Bergsagel P.L., Greipp P.R., et al. Apractical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007, 21:529-534.
    • (2007) Leukemia , vol.21 , pp. 529-534
    • Stewart, A.K.1    Bergsagel, P.L.2    Greipp, P.R.3
  • 8
    • 84055222501 scopus 로고    scopus 로고
    • Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management
    • Rajkumar S.V. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012, 87:78-88.
    • (2012) Am J Hematol , vol.87 , pp. 78-88
    • Rajkumar, S.V.1
  • 9
    • 50449086728 scopus 로고    scopus 로고
    • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
    • San Miguel J.F., Schlag R., Khuageva N.K., et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. NEngl J Med 2008, 359:906-917.
    • (2008) NEngl J Med , vol.359 , pp. 906-917
    • San Miguel, J.F.1    Schlag, R.2    Khuageva, N.K.3
  • 10
    • 84856278440 scopus 로고    scopus 로고
    • Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p
    • Neben K., Lokhorst H.M., Jauch A., et al. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood 2012, 119:940-948.
    • (2012) Blood , vol.119 , pp. 940-948
    • Neben, K.1    Lokhorst, H.M.2    Jauch, A.3
  • 11
    • 78049501226 scopus 로고    scopus 로고
    • Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)
    • Avet-Loiseau H., Leleu X., Roussel M., et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). JClin Oncol 2010, 28:4630-4634.
    • (2010) JClin Oncol , vol.28 , pp. 4630-4634
    • Avet-Loiseau, H.1    Leleu, X.2    Roussel, M.3
  • 12
    • 0343355828 scopus 로고    scopus 로고
    • High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies
    • Avet-Loiseau H., Li J.Y., Facon T., et al. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies. Cancer Res 1998, 58:5640-5645.
    • (1998) Cancer Res , vol.58 , pp. 5640-5645
    • Avet-Loiseau, H.1    Li, J.Y.2    Facon, T.3
  • 13
    • 0037092981 scopus 로고    scopus 로고
    • Myeloma and the t(11;14)(q13;q32): evidence for a biologically defined unique subset of patients
    • Fonseca R., Blood E.A., Oken M.M., et al. Myeloma and the t(11;14)(q13;q32): evidence for a biologically defined unique subset of patients. Blood 2002, 99:3735-3741.
    • (2002) Blood , vol.99 , pp. 3735-3741
    • Fonseca, R.1    Blood, E.A.2    Oken, M.M.3
  • 14
    • 0343049149 scopus 로고    scopus 로고
    • Predictive role of interphase cytogenetics for survival of patients with multiple myeloma
    • Königsberg R., Zojer N., Ackermann J., et al. Predictive role of interphase cytogenetics for survival of patients with multiple myeloma. JClin Oncol 2000, 18:804-812.
    • (2000) JClin Oncol , vol.18 , pp. 804-812
    • Königsberg, R.1    Zojer, N.2    Ackermann, J.3
  • 15
    • 0037441892 scopus 로고    scopus 로고
    • Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants
    • Avet-Loiseau H., Garand R., Lodé L., et al. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood 2003, 101:1570-1571.
    • (2003) Blood , vol.101 , pp. 1570-1571
    • Avet-Loiseau, H.1    Garand, R.2    Lodé, L.3
  • 17
    • 0142151221 scopus 로고    scopus 로고
    • T(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma
    • Garand R., Avet-Loiseau H., Accard F., et al. t(11;14) and t(4;14) translocations correlated with mature lymphoplasmacytoid and immature morphology, respectively, in multiple myeloma. Leukemia 2003, 17:2032-2035.
    • (2003) Leukemia , vol.17 , pp. 2032-2035
    • Garand, R.1    Avet-Loiseau, H.2    Accard, F.3
  • 18
    • 0034502263 scopus 로고    scopus 로고
    • The (11;14)(q13;q32) translocation in multiple myeloma: a morphologic and immunohistochemical study
    • Hoyer J.D., Hanson C.A., Fonseca R., et al. The (11;14)(q13;q32) translocation in multiple myeloma: a morphologic and immunohistochemical study. Am J Clin Pathol 2000, 113:831-837.
    • (2000) Am J Clin Pathol , vol.113 , pp. 831-837
    • Hoyer, J.D.1    Hanson, C.A.2    Fonseca, R.3
  • 19
    • 0042744766 scopus 로고    scopus 로고
    • CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma
    • Robillard N., Avet-Loiseau H., Garand R., et al. CD20 is associated with a small mature plasma cell morphology and t(11;14) in multiple myeloma. Blood 2003, 102:1070-1071.
    • (2003) Blood , vol.102 , pp. 1070-1071
    • Robillard, N.1    Avet-Loiseau, H.2    Garand, R.3
  • 20
    • 27744568383 scopus 로고    scopus 로고
    • Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma
    • Dewald G.W., Therneau T., Larson D., et al. Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma. Blood 2005, 106:3553-3558.
    • (2005) Blood , vol.106 , pp. 3553-3558
    • Dewald, G.W.1    Therneau, T.2    Larson, D.3
  • 21
    • 0036721371 scopus 로고    scopus 로고
    • Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy
    • Moreau P., Facon T., Leleu X., et al. Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. Blood 2002, 100:1579-1583.
    • (2002) Blood , vol.100 , pp. 1579-1583
    • Moreau, P.1    Facon, T.2    Leleu, X.3
  • 22
    • 0033567902 scopus 로고    scopus 로고
    • The addition of interferon or high-dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486
    • Oken M.M., Leong T., Lenhard R.E., et al. The addition of interferon or high-dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Cancer 1999, 86:957-968.
    • (1999) Cancer , vol.86 , pp. 957-968
    • Oken, M.M.1    Leong, T.2    Lenhard, R.E.3
  • 23
    • 84988241358 scopus 로고    scopus 로고
    • International uniform response criteria for multiple myeloma
    • Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
    • (2006) Leukemia , vol.20 , pp. 1467-1473
    • Durie, B.G.1    Harousseau, J.L.2    Miguel, J.S.3
  • 24
    • 79955977910 scopus 로고    scopus 로고
    • Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
    • Rajkumar S.V., Harousseau J.L., Durie B., et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011, 117:4691-4695.
    • (2011) Blood , vol.117 , pp. 4691-4695
    • Rajkumar, S.V.1    Harousseau, J.L.2    Durie, B.3
  • 25
    • 33845382806 scopus 로고
    • Nonparametric estimation from incomplete observations
    • Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958, 53:457-481.
    • (1958) JAm Stat Assoc , vol.53 , pp. 457-481
    • Kaplan, E.L.1    Meier, P.2
  • 26
    • 27144441760 scopus 로고    scopus 로고
    • Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy
    • Gertz M.A., Lacy M.Q., Dispenzieri A., et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005, 106:2837-2840.
    • (2005) Blood , vol.106 , pp. 2837-2840
    • Gertz, M.A.1    Lacy, M.Q.2    Dispenzieri, A.3
  • 27
    • 33847378314 scopus 로고    scopus 로고
    • Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome
    • Avet-Loiseau H., Attal M., Moreau P., et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome. Blood 2007, 109:3489-3495.
    • (2007) Blood , vol.109 , pp. 3489-3495
    • Avet-Loiseau, H.1    Attal, M.2    Moreau, P.3
  • 28
    • 84880447379 scopus 로고    scopus 로고
    • Impact of non high-risk chromosomal abnormalities on the outcome of autologous hematopoietic stem cell transplantation in multiple myeloma [abstract]
    • ASH Annual Meeting Abstracts
    • Ahmed S., Lin H., Baladandayuthapani V., et al. Impact of non high-risk chromosomal abnormalities on the outcome of autologous hematopoietic stem cell transplantation in multiple myeloma [abstract]. Blood 2011, 118:333. ASH Annual Meeting Abstracts.
    • (2011) Blood , vol.118 , pp. 333
    • Ahmed, S.1    Lin, H.2    Baladandayuthapani, V.3
  • 29
    • 77953632707 scopus 로고    scopus 로고
    • Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance
    • Nair B., van Rhee F., Shauqhnessy J.D., et al. Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood 2010, 115:4168-4173.
    • (2010) Blood , vol.115 , pp. 4168-4173
    • Nair, B.1    van Rhee, F.2    Shauqhnessy, J.D.3
  • 30
    • 33847312216 scopus 로고    scopus 로고
    • Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma
    • Qazilbash M.H., Saliba R.M., Hosing C., et al. Autologous stem cell transplantation is safe and feasible in elderly patients with multiple myeloma. Bone Marrow Transplant 2007, 39:279-283.
    • (2007) Bone Marrow Transplant , vol.39 , pp. 279-283
    • Qazilbash, M.H.1    Saliba, R.M.2    Hosing, C.3
  • 31
    • 84860219808 scopus 로고    scopus 로고
    • Arandomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid
    • Sharma M., Khan H., Thall P.F., et al. Arandomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid. Cancer 2012, 118:2507-2515.
    • (2012) Cancer , vol.118 , pp. 2507-2515
    • Sharma, M.1    Khan, H.2    Thall, P.F.3
  • 32
    • 20644460600 scopus 로고    scopus 로고
    • International staging system for multiple myeloma
    • Greipp P.R., Miguel J.S., Durie B.G., et al. International staging system for multiple myeloma. JClin Oncol 2005, 23:3412-3420.
    • (2005) JClin Oncol , vol.23 , pp. 3412-3420
    • Greipp, P.R.1    Miguel, J.S.2    Durie, B.G.3
  • 33
    • 33645706760 scopus 로고    scopus 로고
    • Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients
    • O'Shea D., Giles C., Terpos E., et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 2006, 37:731-737.
    • (2006) Bone Marrow Transplant , vol.37 , pp. 731-737
    • O'Shea, D.1    Giles, C.2    Terpos, E.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.